Latest News

Scholar Rock Issues Community Statement with Update on SRK-015 in Patients with Types 2 and 3 SMA

October 27, 2020
Posted in , ,

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced 6-month interim results from their clinical […]

Read More ›

Community Spotlight: Perspectives from Spencer Cook, Registered Accessibility Specialist

October 26, 2020
Posted in ,

October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we have been posting stories about adults with SMA in the workforce and […]

Read More ›

Community Spotlight: Kayley Shade of Sioux Falls Storm

October 19, 2020
Posted in ,

October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we will be posting stories about adults with SMA in the workforce and […]

Read More ›

NeurologyLive Article Now Available, Featuring an Interview with Cure SMA’s Dr. Mary Schroth

October 8, 2020
Posted in , ,

    Through Cure SMA’s partnership with NeurologyLive, a new patient-centered article, “Early Intervention in SMA: How Access to Therapy Will Alter Disease Management As We Know It,” is now […]

Read More ›

Community Spotlight: AJ Brockman of Brewhouse Gallery and Kelsey City Brewing Company

October 8, 2020
Posted in

October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we will be posting stories about adults with SMA in the workforce and […]

Read More ›

Cure SMA Publishes Paper in Partnership with NeurologyLive on Impact of COVID-19

October 2, 2020
Posted in , ,

    Cure SMA has published a paper, titled “Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers,” in partnership with NeurologyLive. The article highlights findings from a recent […]

Read More ›
Scroll to Top